Warfarin Management After Interruption with Subtherapeutic INR
Resume warfarin at the patient's usual maintenance dose of 10 mg daily and recheck INR in 3-5 days, as the current INR of 1.0 after 3 days of restarting indicates the patient is still in the early phase of re-anticoagulation where full effect has not yet been achieved.
Rationale for Continuing Current Dose
The FDA label clearly states that "the full anticoagulant effect of COUMADIN is not achieved for several days" 1. After a 5-day interruption, the patient's clotting factors have normalized, and restarting warfarin 3 days ago means you're only partway through the expected time to therapeutic effect.
Key principle: Warfarin's anticoagulant effect persists beyond 24 hours, and steady-state anticoagulation typically requires 4-5 days of consistent dosing 1. Your patient has only received 3 days of the restarted regimen.
Why Not to Increase the Dose Yet
- Avoid overreaction: Research demonstrates that in stable patients with occasional out-of-range INRs, continuing the maintenance dose without adjustment often achieves therapeutic range within 2 weeks 2
- Loading doses show minimal benefit: A randomized trial found that loading doses (1.5x maintenance) shortened time to INR ≥2.0 by only 1.2 days compared to maintenance dosing (7.8 vs 9.0 days), which was not statistically significant 3
- Risk of overcorrection: Premature dose escalation can lead to supratherapeutic INR values once the cumulative effect manifests
Monitoring Strategy
Recheck INR in 3-5 days (making it 6-8 days total since restart):
- If INR remains <1.5 at day 6-8: Consider modest dose increase (10-20% above maintenance)
- If INR 1.5-1.9: Continue current dose, recheck in another 3-5 days
- If INR ≥2.0: Continue maintenance dose with routine monitoring
High-Risk Patients Requiring Bridging
Critical exception: If this patient has a high thrombotic risk condition (mechanical heart valve, recent VTE within 3 months, or history of thrombosis while anticoagulated), consider bridging with therapeutic-dose LMWH until INR ≥2.0 4, 5.
The 2022 CHEST guidelines recommend bridging for high-risk patients with full-dose subcutaneous LMWH (enoxaparin 1 mg/kg BID or 1.5 mg/kg daily) until therapeutic INR is achieved 5.
Common Pitfalls to Avoid
- Don't double the dose: The FDA label explicitly warns against doubling doses to compensate for subtherapeutic levels 1
- Don't assume resistance prematurely: Three days is insufficient time to judge warfarin response
- Don't forget drug/dietary interactions: Verify no new medications or significant dietary vitamin K changes that could affect response
- Consider patient-specific factors: Elderly patients (≥75 years) typically require 1 mg/day less than younger patients and show greater INR sensitivity 4